Baseline Quality of Life Predicts Survival in mCRPC Patients Treated with 223Ra

173 metastatic castration-resistant prostate cancer patients were prospectively studied to evaluate the impact of baseline Quality of Life on Overall Survival. The study assessed patient-reported QoL using EORTC QLQ-C30 and QLQ-BM22 questionnaires, compiling 2264 questionnaires over the treatment and follow-up period. Researchers from Sapienza University of Rome performed multivariate analysis and joint models to identify baseline QoL as a significant independent predictor of survival.

Use Cases

• Predicting overall survival in mCRPC patients based on baseline clinical parameters like hemoglobin and alkaline phosphatase.
• Analyzing the relationship between patient-reported quality of life scores and treatment efficacy.
• Building joint models for survival and longitudinal data to track QoL deterioration during therapy and follow-up.
• Identifying significant predictors from questionnaire data using principal component analysis.

Strengths

• Prospective study design with 173 consecutive patients.
• Longitudinal data from 2264 patient-reported questionnaires.
• Multivariate analysis identifies specific QoL items (physical functioning, dyspnea) as significant predictors.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count for the underlying dataset is unknown, which may limit suitability assessment.
• Data may reflect temporal and institutional bias inherent to a single-center study.

Provenance

Source

Sapienza University of Rome

Collection Method

Prospective clinical study of patients treated with 223Ra-dichloride.